AU2017229105B2 - Methods and compositions for treatment of Zika virus infection - Google Patents

Methods and compositions for treatment of Zika virus infection Download PDF

Info

Publication number
AU2017229105B2
AU2017229105B2 AU2017229105A AU2017229105A AU2017229105B2 AU 2017229105 B2 AU2017229105 B2 AU 2017229105B2 AU 2017229105 A AU2017229105 A AU 2017229105A AU 2017229105 A AU2017229105 A AU 2017229105A AU 2017229105 B2 AU2017229105 B2 AU 2017229105B2
Authority
AU
Australia
Prior art keywords
zika virus
compound
day
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017229105A
Other languages
English (en)
Other versions
AU2017229105A1 (en
Inventor
Yarlagadda S. Babu
Shanta Bantia
Pravin L. Kotian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of AU2017229105A1 publication Critical patent/AU2017229105A1/en
Application granted granted Critical
Publication of AU2017229105B2 publication Critical patent/AU2017229105B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017229105A 2016-03-06 2017-03-06 Methods and compositions for treatment of Zika virus infection Active AU2017229105B2 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662304317P 2016-03-06 2016-03-06
US62/304,317 2016-03-06
US201662324180P 2016-04-18 2016-04-18
US62/324,180 2016-04-18
US201662368111P 2016-07-28 2016-07-28
US62/368,111 2016-07-28
US201662370697P 2016-08-03 2016-08-03
US62/370,697 2016-08-03
US201662411867P 2016-10-24 2016-10-24
US62/411,867 2016-10-24
US201662414466P 2016-10-28 2016-10-28
US62/414,466 2016-10-28
US201762462852P 2017-02-23 2017-02-23
US62/462,852 2017-02-23
PCT/US2017/020961 WO2017155886A1 (en) 2016-03-06 2017-03-06 Methods and compositions for treatment of zika virus infection

Publications (2)

Publication Number Publication Date
AU2017229105A1 AU2017229105A1 (en) 2018-10-11
AU2017229105B2 true AU2017229105B2 (en) 2021-08-12

Family

ID=59789791

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017229105A Active AU2017229105B2 (en) 2016-03-06 2017-03-06 Methods and compositions for treatment of Zika virus infection

Country Status (9)

Country Link
US (3) US10512649B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426659A4 (cg-RX-API-DMAC7.html)
JP (1) JP7046015B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017229105B2 (cg-RX-API-DMAC7.html)
CA (1) CA3016588A1 (cg-RX-API-DMAC7.html)
MA (1) MA43812A (cg-RX-API-DMAC7.html)
MX (1) MX381542B (cg-RX-API-DMAC7.html)
TW (1) TWI767903B (cg-RX-API-DMAC7.html)
WO (1) WO2017155886A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7416445B2 (ja) * 2019-02-18 2024-01-17 株式会社栄養・病理学研究所 ブタにおけるt細胞の活性化度を評価する方法、ブタにおけるt細胞活性化を評価する剤、ブタt細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051230A1 (en) * 2010-10-15 2015-02-19 Biocryst Pharmaceuticals, Inc. Methods and Compositions for Inhibition of Polymerase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ES2362805T3 (es) 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
US20100129317A1 (en) 2006-09-11 2010-05-27 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051230A1 (en) * 2010-10-15 2015-02-19 Biocryst Pharmaceuticals, Inc. Methods and Compositions for Inhibition of Polymerase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE, 2014, vol. 508, no. 7496, pages 402 - 405 *
VIRUSDISEASE, 2016, vol. 27, no. 2, pages 111 - 115. *

Also Published As

Publication number Publication date
TW201731515A (zh) 2017-09-16
US20200085830A1 (en) 2020-03-19
EP3426659A1 (en) 2019-01-16
CA3016588A1 (en) 2017-09-14
US20190083496A1 (en) 2019-03-21
AU2017229105A1 (en) 2018-10-11
MX381542B (es) 2025-03-04
JP2019507195A (ja) 2019-03-14
US10512649B2 (en) 2019-12-24
MA43812A (fr) 2018-11-28
JP7046015B2 (ja) 2022-04-01
MX2018010707A (es) 2019-03-28
EP3426659A4 (en) 2019-12-25
TWI767903B (zh) 2022-06-21
WO2017155886A1 (en) 2017-09-14
US11975003B2 (en) 2024-05-07
US10933066B2 (en) 2021-03-02
US20210186976A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
AU2017200471B2 (en) Methods and compositions for inhibition of polymerase
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
JP5854841B2 (ja) デングウイルス感染を治療及び予防するためのチエノピリジン誘導体類
KR20120049852A (ko) 뎅기 바이러스 감염의 치료 및 예방
CN101743008A (zh) 用于治疗或预防登革热感染的抗病毒药
US20240261313A1 (en) Kit for preventing or treating filovirus and flavivirus diseases
US20210353564A1 (en) Treatments for zika virus infection
US11975003B2 (en) Methods and compositions for treatment of Zika virus infection
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
CN104203228A (zh) 具有抗黄病毒的抗病毒活性的组合物
Wutzler et al. Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports
US12472197B2 (en) Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
KR102590444B1 (ko) Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR102590438B1 (ko) Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
CN114980885A (zh) 治疗hiv-1感染的方法
US20170348330A1 (en) Antiviral compound and analogues thereof for treatment or prevention of flavivirus dengue/zika infections
EP3960173B1 (en) Enterovirus inhibitor
Chen et al. Tolvaptan, an FDA-approved drug, inhibits Zika virus infection both in vitro and in vivo.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)